- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02472080
Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study (THYGEMOX)
Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients
Radioiodine refractory differentiated thyroid cancer is a rare tumor and therapeutic options are limited in this setting. Molecular targeted therapies have recently been developed for progressive disease and demonstrated clinical activity, especially with anti-angiogenic agents.
For patients with contra-indication to these agents or in case of progression or toxicity during treatment, chemotherapy is usually proposed but this strategy has not been validated by prospective data.
The investigators propose to conduct an open single arm phase 2 study to evaluate response rate according to RECIST 1.1 with GEMOX regimen (gemcitabine - oxaliplatin combination) for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim is to study efficacy of chemotherapy with gemcitabine - oxaliplatin combination for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.
For refractory thyroid cancer patients, in case of contra-indication to molecular targeted therapies or in case of progression or toxicity during treatment, alternative treatments are urgently needed.
Our study could precise if cytotoxic agents should remain a treatment option for refractory thyroid cancer after molecular targeted therapies or in case of contra-indication.
Numerous clinical trials are proposed to evaluate various molecular targeted therapies for refractory thyroid cancer, either conducted by institutional or industrial promoters. In contrast, chemotherapy trials are lacking. As generics are actually available for gemcitabine and oxaliplatin, no industrial support can be expected and prospective evaluation a chemotherapy regimen need to be conducted by an institutional promoter ("Assistance Publique - Hôpitaux de Paris"), supported by many French expert teams through the rare tumor network ""TUTHYREF"".
GEMOX regimen will be administrated intravenously every two weeks in ambulatory setting.
The objective of this study is to analyse the efficacy of chemotherapy with gemcitabine - oxaliplatin combination for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.
The primary end point is overall response rate (complete + partial response - CR+PR), according to RECIST 1.1, assessed by local investigator at 4 months.
30 patients will be included in a two steps design (Fleming design). A response rate lower than 15% define the inefficacy level. Minimal efficacy should be 35% response rate.
First step: inclusion of 15 patients. If 2 or less responses are observed: end of study for inefficacy If 6 or more responses are observed: efficacy endpoint has been reached If 3 to 5 responses are observed, additional inclusions are needed. Second step: inclusion of 15 additional patients. Nine responses are expected to define a positive study. Details are presented in statistical section.
The secondary end points are:
- Safety report according to NCI CTCAE v 4.0 grading scale
- Early metabolic response rate on 18F-FDG-PET/CT at 2 months
- Disease control rate (DCR = CR + PR + SD) ≥ 6 months
- Duration of response
- Time to progression
- Progression free survival
- Overall survival.
- Evolution of quality of life according to Fact-G and EQ-5D "
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Groupe Hospitalier Pitié Salpétrière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
"Main Inclusion criteria
- Histologically confirmed differentiated or poorly differentiated thyroid cancer that is metastatic or unresectable
- Patients refractory to radio iodine
- Radiologic evidence of clinically relevant disease progression (as per RECIST 1.1)
- Measurable disease (by RECIST Version 1.1 criteria)
- ECOG performance status of ≤ 1
- Adequate hematologic, renal and liver function
- Negative serum pregnancy test in premenopausal women.
- Signed informed consent
Main Non-Inclusion criteria
- Other histological subtypes of thyroid tumors: anaplastic, medullary, lymphoma or sarcoma
- Active CNS metastases
- Prior chemotherapy. Patients treated previously with molecular targeted therapies could be included.
- Severe, acute or chronic medical or psychiatric condition or laboratory abnormality which in the judgment of the investigator would make the patient inappropriate for entry into this study"
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: gemcitabine -oxaliplatine combination
|
gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate
Time Frame: 4 months
|
overall response rate measured (complete and partial responses) by CT-scan according to RECIST criteria v1.1
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of adverse events and serious adverse events (AE) according to CTCAE v4.03
Time Frame: up to 12 month
|
recording number of adverse events and serious adverse events (AE) according to CTCAE v4.03, during chemotherapy and follow up.
|
up to 12 month
|
Early metabolic response rate on 18F-FDG-TEP/CT
Time Frame: 2 months
|
semi-quantitative PET Response Criteria in Solid Tumors PERCIST1.0
"modified" using SUVmax and body-weight.
Central reviewing of FDG-PET data by two readers at the end of the study will be done.
|
2 months
|
Disease control rate
Time Frame: 4 months
|
Disease control rate (DCR) is defined as the percentage of patients who have achieved complete response (CR), partial response (PR) or stable disease (SD).
|
4 months
|
Time to progression
Time Frame: up to 36 months
|
Time from documentation of tumor response to disease progression or date of death from any cause
|
up to 36 months
|
Progression free survival
Time Frame: up to 36 months
|
Time from documentation of tumor response to disease progression or date of death from any cause
|
up to 36 months
|
Overall survival
Time Frame: up to 36 months
|
Delay between inclusion and death from any cause
|
up to 36 months
|
Quality of life
Time Frame: at day 1(week 1, i.e first cycle) and repeated every 28 days (i.e at W5, W9, W13, W17) during chemotherapy and every 3 months until 12 months
|
evolution of quality of life will be assessed by the scores at the FACT-G and EQ-5D surveys (French version)
|
at day 1(week 1, i.e first cycle) and repeated every 28 days (i.e at W5, W9, W13, W17) during chemotherapy and every 3 months until 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Laurence Leenhardt, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Thyroid Diseases
- Thyroid Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Oxaliplatin
Other Study ID Numbers
- P130933
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
Massachusetts General HospitalEli Lilly and CompanyRecruitingThyroid Carcinoma | Thyroid Cancer | Papillary Thyroid Cancer | Metastatic Thyroid Cancer | Follicular Thyroid Cancer | Unresectable Thyroid Gland CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
Clinical Trials on gemcitabine -oxaliplatine combination
-
The Lymphoma Academic Research OrganisationInnate PharmaRecruitingPeripheral T Cell Lymphoma | Relapse/RecurrenceFrance, Spain, Belgium, Germany
-
Centre Hospitalier Universitaire de BesanconTerminatedMetastatic Pancreatic AdenocarcinomaFrance
-
HutchmedCompletedLymphoma | Osteosarcoma | Solid Tumor | Ewing Sarcoma | Rhabdomyosarcoma | Non-rhabdomyosarcoma Soft Tissue SarcomaUnited States
-
Fudan UniversityCompleted
-
SanofiCompletedNon Small Cell Lung CancerFrance
-
RemeGen Co., Ltd.Recruiting
-
The Lymphoma Academic Research OrganisationPfizerCompletedDiffuse Large B-Cell LymphomaFrance, Belgium
-
PfizerTerminatedNon-small Cell Lung Cancer | Urothelial CancerSpain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
-
University of Alabama at BirminghamEli Lilly and CompanyCompletedStage IV Non-Small Cell Lung CancerUnited States
-
Karyopharm Therapeutics IncRecruitingRelapsed/Refractory Diffuse Large B-cell LymphomaUnited States, Spain, Israel, Italy, Poland, China, Austria